Welcome to our dedicated page for ReShape Lifesciences SEC filings (Ticker: RSLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The journey from LAP-BAND® sales to the upcoming Diabetes Bloc-Stim neuromodulation trials means Reshape Lifesciences crams FDA milestones, clinical data, and cash-burn details into every SEC document. Finding the revenue split between the adjustable gastric band and Obalon Balloon, or pinpointing when RSLS last updated its expected regulatory timeline, can take hours.
Stock Titan’s AI reads each new Reshape Lifesciences quarterly earnings report 10-Q filing the moment it lands on EDGAR, extracts segment revenue, and flags liquidity warnings in plain English. Need Reshape Lifesciences insider trading Form 4 transactions? We stream Reshape Lifesciences Form 4 insider transactions real-time so you can spot executive stock moves before the market reacts. Our summaries turn a 300-page Reshape Lifesciences annual report 10-K simplified into concise bullet points, and every Reshape Lifesciences 8-K material events explained section highlights trial results or device recalls in seconds.
Whether you’re computing dilution risk ahead of the next capital raise, comparing reimbursement assumptions, or reviewing the Reshape Lifesciences proxy statement executive compensation, our platform answers natural questions like “understanding Reshape Lifesciences SEC documents with AI” and “Reshape Lifesciences earnings report filing analysis.” Stop sifting through exhibits; monitor pipeline progress, R&D spend, and Reshape Lifesciences executive stock transactions Form 4 in one place—with real-time alerts and expert context that help you act with confidence.
Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.
John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.
Robert Dickey IV, Chief Financial Officer and Director of Vyome Holdings, Inc., reported a change in beneficial ownership related to a merger involving Vyome Therapeutics. The reporting person received 762 shares of Vyome Holdings common stock on 08/15/2025 in exchange for 3,810,000 shares of Vyome Therapeutics common stock under the Merger Agreement, which converted every 5,000 Vyome Therapeutics shares into one share of the issuer. The Merger resulted in Vyome Therapeutics becoming a subsidiary of the issuer and the renamed parent company Vyome Holdings, Inc. The Form 4 discloses the acquisition as a non-derivative transaction and indicates the reporting person holds the shares directly.
Venkateswarlu Nelabhotla filed an SEC Form 3 reporting his initial statement of beneficial ownership with respect to Vyome Holdings, Inc. (ticker HIND). The filing, tied to an event dated 08/15/2025, identifies him as both President & CEO and a director. The Form 3 states no securities are beneficially owned by the reporting person. The form is signed and dated 09/11/2025.
Vyome Holdings, Inc. (ticker HIND) filed an Initial Statement of Beneficial Ownership (Form 3) for Robert Dickey IV, who is identified as the company’s Chief Financial Officer and a director. The filing reports the qualifying event date as 08/15/2025 and is signed on 09/11/2025. The form states explicitly that no securities are beneficially owned by the reporting person at the time of filing, meaning Mr. Dickey disclosed no direct or indirect ownership of the issuer’s equity or derivative securities in this submission.
FAQ
What is the current stock price of ReShape Lifesciences (RSLS)?
What is the market cap of ReShape Lifesciences (RSLS)?
